PDF herunterladen
CC BY-NC-ND 4.0 · South Asian J Cancer 2020; 09(01): 22-29
DOI: 10.4103/sajc.sajc_166_19
Letter to the Editor

A rare case of hyperprogression of nonsmall cell lung cancer in a patient on atezolizumab therapy

Sudarsan Vishnu Kollimuttathuillam
Department of Medical Oncology, St Michael's Medical Center, Newark, NJ, an Affiliate of New York Medical College, Westchester, NY
,
Supreet Kaur
Department of Medical Oncology, St Michael's Medical Center, Newark, NJ, an Affiliate of New York Medical College, Westchester, NY
,
Hamid Shaaban
Department of Medical Oncology, St Michael's Medical Center, Newark, NJ, an Affiliate of New York Medical College, Westchester, NY
,
Gunwant Guron
Department of Medical Oncology, St Michael's Medical Center, Newark, NJ, an Affiliate of New York Medical College, Westchester, NY
› Institutsangaben Financial support and sponsorship: Nill.
› Weitere Informationen
Auch verfügbar auf
  als PDF herunterladen Lizenzen und Reprints


Publikationsverlauf

Artikel online veröffentlicht:
14. Dezember 2020

© 2020. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 2017;23:1920-8.
  • 2 Saâda-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2017;28:1605-11.
  • 3 Soria F, Beleni AI, D'Andrea D, Resch I, Gust KM, Gontero P, et al. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. World J Urol 2018;36:1703-9.
  • 4 Salhan D, Verma P, Basunia M. Unusual presentation of clostridium difficile: Hepatic portal venous gas and gastric emphysema. Chest 2016;150:264A.
  • 5 Yoshida T, Furuta H, Hida T. Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence. Med Oncol 2017;34:34.
  • 6 Chubachi S, Yasuda H, Irie H, Fukunaga K, Naoki K, Soejima K, et al. A case of non-small cell lung cancer with possible “disease flare” on nivolumab treatment. Case reports in oncological medicine. 2016;2016.
  • 7 Ferrara R, Caramella C, Texier M, Audigier Valette C, Tessonnier L, Mezquita L, et al. 1306PDHyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO). Ann Oncol 2017;28(suppl_5).
  • 8 Singavi AK, Menon S, Kilari D, Alqwasmi A, Ritch PS, Thomas JP, et al, George B. 1140PDPredictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI)–analysis of somatic alterations (SAs). Ann Oncol 2017;28(suppl_5).
  • 9 Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after immunotherapy: Analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res 2017;23:4242-50.